Data Insights

Risk adjusted net present value: What is the current valuation of AstraZeneca's Volrustomig?

Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Cervical Cancer. According to Globaldata,...

Net Present Value Model: AstraZeneca Plc's Volrustomig

Data Insights

Volrustomig by AstraZeneca for Hepatocellular Carcinoma: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Hepatocellular Carcinoma

Data Insights

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Cervical Cancer

Data Insights

Volrustomig by AstraZeneca for Non-Small Cell Lung Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Non-Small Cell Lung Cancer

Data Insights

Volrustomig by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Squamous Non-Small Cell Lung Cancer

Data Insights

Volrustomig by AstraZeneca for Malignant Pleural Mesothelioma: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Malignant Pleural Mesothelioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Malignant Pleural Mesothelioma

Data Insights

Volrustomig by AstraZeneca for Hypopharyngeal Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Hypopharyngeal Cancer

Data Insights

Volrustomig by AstraZeneca for Laryngeal Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Laryngeal Cancer

Data Insights

Volrustomig by AstraZeneca for Oropharyngeal Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Oropharyngeal Cancer

Data Insights

Volrustomig by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Oral Cavity (Mouth) Cancer

Data Insights

Volrustomig by AstraZeneca for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Volrustomig by AstraZeneca for Rhabdomyosarcoma: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Rhabdomyosarcoma

Data Insights

Volrustomig by AstraZeneca for Leiomyosarcoma: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Leiomyosarcoma

Data Insights

Volrustomig by AstraZeneca for Pleomorphic Liposarcoma: Likelihood of Approval

Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Pleomorphic Liposarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Pleomorphic Liposarcoma